Substituted 5-(phenoxyalkanoylamino)-uracil compounds, methods for making same and pharmaceutical compositions based on same

US5185341A · kind A · utility

Assignee

• Arzneimittelwerk Dresden GmbH · DE

Inventors

• Wolfgang Sauer · Everberg, BE
• Hans-Joachim Jansch · Radebeul, DE
• Angelika Rostock · Dresden, DE
• Gottfried Faust · Berlin, DE
• Christine Siegemund · Weinböhla, DE
• Dieter Lohmann · Münchenstein, CH
• Reni Bartsch · Dresden, DE

Key dates

• Filing date: Nov 4, 1991
• Grant date: Feb 9, 1993
• Expiry date: Nov 4, 2011

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The substituted 5-(phenoxyalkanoylamino)-uracil compounds have the following formula I: ##STR1## wherein R.sub.1 and R.sub.2 are each independently hydrogen; a branched or linear alkyl group having 1 to 6 carbon atoms; a branched or straight chain alkenyl or alkynyl group having 1 to 6 carbons atoms; a cycloalkyl group having from 3 to 7 carbon atoms or a cycloalkylmethyl group having a cycloalkyl residue of 3 to 7 carbon atoms; or a phenylalkyl group having an alkyl residue having from 1 to 3 carbon atoms and a phenyl residue, the phenyl residue being unsubstituted or having a halogen, methoxy, methyl or trifluoromethyl substituent; R.sub.3 is a hydrogen, methyl or amino groups; R.sub.4 is halogen, methoxy or methyl groups, and n is 1 or 2. Pharmaceutical compositions for treating cerebrovascular, neuronal-degenerative and senility-induced disorders associated with learning, memory and cognitive dysfunctions are described which contain a therapeutically effective amount of the substituted 5-(phenoxyalkanoylamino)-uracil in a pharmaceutically acceptable carrier.